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CORRESPONDENCE
Letters to the Editor
Cardioprotection by Volatile
Anesthetics in Noncardiac
Surgery? No, Not Yet At Least
In the recently published article by Fleisher et al. (1), the authors
advise using volatile anesthetics as cardioprotective agents in
patients at risk for myocardial ischemia undergoing noncardiac
surgery. These drugs have indeed shown marked cardioprotective
properties in cardiac surgery, reducing post-operative mortality and
myocardial infarction rate when compared with total intravenous
anesthesia (2).
No study to date has allowed these interesting results to be
translated in noncardiac surgery settings. A recent meta-analysis
including more than 80 randomized controlled studies in which
volatile anesthetics were compared with total intravenous anesthesia
in noncardiac surgery highlighted the complete lack of published
randomized clinical trials reporting data regarding postoperative
mortality or cardiac complications after noncardiac surgery (3),
which indicates that cardioprotection by halogenated anesthetics in
noncardiac surgery is a new and interesting subject that deserves
further study.
Because the authors of the guidelines suggest a class of evidence
IIA, level B (“some conflicting evidence from single randomized
trial or non-randomized studies”), we would appreciate knowing
which article(s) provided the evidence to state that “it can be
beneficial to use volatile anesthetic agents during noncardiac
surgery for the maintenance of general anesthesia in hemodynam-
ically stable patients at risk for myocardial ischemia.”
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Reply
There is intense interest in the actions of volatile anesthetics agents
to pre- and post-condition myocardium against injury after myo-
cardial ischemia and reperfusion. Anesthetic pre-conditioning was
first demonstrated in animal models in 1997 (1,2) and in patients
undergoing coronary artery bypass graft surgery in 1999 (3). The
American College of Cardiology/American Heart Association
2007 Guidelines on Perioperative Cardiovascular Evaluation and
Care for Noncardiac Surgery (4) summarize the findings of 15
randomized clinical trials in patients undergoing coronary artery
bypass graft surgery demonstrating that volatile anesthetic agents
decrease troponin release and enhance left ventricular function
compared with several intravenous anesthetics. Studies designed to
evaluate the efficacy of anesthetic pre- or post-conditioning against
myocardial injury have been conducted in patients undergoing
cardiac surgery because the timing and duration of the myocardial
ischemic stimulus is relatively well defined. In addition, the
majority of these investigations controlled for important variables
that could influence anesthetic cardioprotection, such as by dis-
continuing sulfonylurea hypoglycemic agents that block anesthetic
pre- and post-conditioning. The data indicate that volatile
anesthetic agents are protective against myocardial ischemia/
reperfusion injury and can likely be generalized to patients with
coronary artery disease undergoing noncardiac surgery. To date,
there have been no published studies specifically designed to assess
the efficacy of anesthetic pre- or post-conditioning against myo-
cardial injury in patients undergoing noncardiac surgery. Also,
volatile anesthetics produce important negative inotropic effects,
and the risks and benefits of these drugs in hemodynamically
unstable patients are unclear. There is a great need for further
investigation in this area. The conduct of adequately powered and
well-controlled studies of anesthetic cardioprotection in noncar-
diac surgical patients will be challenging. Meta-analyses of heter-
ogeneous clinical trials using volatile or intravenous anesthetics in
patients who are at low or intermediate risk for developing
myocardial ischemia due to the nature of the surgical procedure,
the burden of disease, or both may not be adequate to elucidate the
risks versus benefits of specific anesthetic agents to produce
cardioprotection. Per the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines
Methodology, unpublished data cannot be used to formulate
guideline recommendations. Thus, the weight of the evidence
suggests that volatile anesthetics are protective against myocardial
ischemia/reperfusion injury, and in the absence of data to indicate
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